New hope for kids on dialysis: drug targets overactive glands
NCT ID NCT03969329
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests the drug etelcalcetide (Parsabiv) in 24 children aged 2 to 17 with secondary hyperparathyroidism due to chronic kidney disease who are on hemodialysis. The goal is to see if the drug can safely lower parathyroid hormone levels and improve mineral balance. The study is open-label and everyone gets the drug, with no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etelcalcetide (Parsabiv)
- What this could lead to
- If successful, this could provide a new treatment option to help control hormone levels and mineral balance in children with kidney disease on dialysis.
- What could go wrong
- This is a small, single-arm study with no placebo group, so results may be less reliable. Side effects like low calcium or gastrointestinal issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Azienda Ospedaliera Universitaria Meyer
TERMINATEDFlorence, 50139, Italy
-
Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos
TERMINATEDVilinus, 08406, Lithuania
-
Fakultni nemocnice v Motole
COMPLETEDPrague, 150 06, Czechia
-
General Children Hospital Panagioti and Aglaias Kyriakou
RECRUITINGAthens, 11527, Greece
-
Great Ormond Street Hospital for Children
TERMINATEDLondon, WC1N 3JH, United Kingdom
-
Hopital Armand Trousseau
COMPLETEDParis, 75012, France
-
Hospices Civils de Lyon Hopital Femme Mere Enfant
TERMINATEDBron, 69677, France
-
Hospital Universitari Vall d Hebron
RECRUITINGBarcelona, Catalonia, 08035, Spain
-
Hospital Universitario Virgen del Rocio
TERMINATEDSeville, Andalusia, 41013, Spain
-
Ippokrateio General Hospital of Thessaloniki
RECRUITINGThessaloniki, 54642, Greece
-
Kindernierenzentrum Bonn
COMPLETEDBonn, 53127, Germany
-
Leeds Teaching Hospitals NHS Trust
RECRUITINGLeeds, LS1 3EX, United Kingdom
-
Medizinische Hochschule Hannover
COMPLETEDHanover, 30625, Germany
-
Royal Hospital for Sick Children
RECRUITINGGlasgow, G51 4TF, United Kingdom
-
Semmelweis Egyetem
TERMINATEDBudapest, 1083, Hungary
-
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar
TERMINATEDSzeged, 6720, Hungary
-
Unidade Local de Saude de Santo Antonio, EPE - Hospital de Santo Antonio
RECRUITINGPorto, 4050-651, Portugal
-
Universitaetsklinikum Hamburg Eppendorf
RECRUITINGHamburg, 20246, Germany
-
Universitaetsklinikum Heidelberg, Zentrum fuer Kinder und Jugendmedizin
RECRUITINGHeidelberg, 69120, Germany
-
Universitaetsklinikum Koeln
RECRUITINGCologne, 50937, Germany
-
Universitair Ziekenhuis Gent
TERMINATEDGhent, 9000, Belgium
-
University Hospital Southampton NHS Foundation Trust
RECRUITINGSouthampton, SO16 6YD, United Kingdom
-
Uniwersytecki Szpital Dzieciecy w Krakowie
TERMINATEDKrakow, 30-663, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk